Further, some genetic abnormalities, such as a loss of phosphatase and tensin homolog in glioma or triple-negative breast cancer, and epidermal growth factor receptor mutations in lung cancer, can directly upregulate PD-L1 on cancer cells [24, 40, 41]. This evidence concerns the gene EGFR and central nervous system cancer.